Sandoz, a Novartis division, announced that it has signed a Memorandum of Understanding, or MOU, to build a new biologics production plant in Lendava, Slovenia. The Sandoz investment is expected to be at least $400M, "supporting the company’s ambition to drive the future growth of its global biosimilars portfolio." This represents "one of the largest-ever international private-sector investments in Slovenia," the company added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Voyager announces Novartis exercised option to license novel capsids for $25M
- Novartis treatment of multiple myeloma granted orphan designation
- Avrobio exploring potential sale after approach, Street Insider says
- Immix Biopharma doses first two patients in Phase 1b/2a combination trial
- Novartis’ Sandoz BLA for proposed biosimilar denosumab accepted by FDA